Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Generic drugs [[electronic resource] ] : the pay-for-delay problem / / Christina M. Curtin, editor
| Generic drugs [[electronic resource] ] : the pay-for-delay problem / / Christina M. Curtin, editor |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2011 |
| Descrizione fisica | 1 online resource (138 p.) |
| Disciplina | 338.4/361510973 |
| Altri autori (Persone) | CurtinChristina M |
| Collana | Public health in the 21st century |
| Soggetto topico |
Generic drugs - Prices
Drugs - Prices Pharmaceutical industry - United States |
| ISBN | 1-61122-360-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910789744603321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Generic drugs : the pay-for-delay problem / / Christina M. Curtin, editor
| Generic drugs : the pay-for-delay problem / / Christina M. Curtin, editor |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2011 |
| Descrizione fisica | 1 online resource (138 p.) |
| Disciplina | 338.4/361510973 |
| Altri autori (Persone) | CurtinChristina M |
| Collana | Public health in the 21st century |
| Soggetto topico |
Generic drugs - Prices
Drugs - Prices Pharmaceutical industry - United States |
| ISBN | 1-61122-360-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions -- Summary -- Recommendation -- Background -- Findings from Pharmaceutical Agreement Filings from FY2004 through FY2009 -- Study Methodology -- How Staff Calculated the Additional Delay in Generic Entry Associated with Agreements that Involved Compensation from the Brand to the Generic -- How Staff Calculated the Estimate of 3.5 Billion Annually that Consumers Lose due to Pay-For-Delay Agreements -- (1) Consumer savings from generic competition -- (2) Likelihood of Settlements with Payment to Delay, and the Length of Delay -- (3) Sales Volume of Drugs for which Settlements are Likely -- (4) Final Estimate Calculation -- Results with Varied Assumptions -- End Notes -- "Pay-for-Delay" Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The 35 Billion Solution) -- A Brief History -- New FTC Analysis of Empirical Data -- Savings to Consumers and the Federal Government -- Encouraging Signs -- Looking Forward -- Appendix: Calculation of Consumer Savings -- Consumer Savings from Generic Competition -- Likelihood of Settlements with Payment to Delay, and the Length of Delay -- Sales Volume of Drugs for which Settlements are Likely -- Final Estimate Calculation -- Results with Varied Assumptions -- End Notes -- Statement of the Federal Trade Commission, before the Subcommittee on Courts and43 -- Competition Policy, Hearing on "Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry: Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs" -- I. The Need for a Legislative Solution.
A. Permissive Court Decisions have Made Pay-for-Delay Settlements Commonplace in Hatch-Waxman Patent Cases -- B. The Profitability of Delaying Generic Entry Means that these Agreements will become More Prevalent -- C. Pay-For-Delay Settlements Impose Enormous Costs on Consumers and the Health Care System -- D. Permissive Legal Treatment of Pay-for-Delay Settlements Undermines the Hatch-Waxman Act -- E. Legislation is Likely to be Swifter and More Comprehensive than Litigation -- II. The Arguments against Barring Exclusion Payments Are Contradicted by Experience in the Market -- III. The Legislative Remedy -- Conclusion -- End Notes -- Testimony of Heather Bresch, Chief Operating Officer, Mylan, Inc., before the Subcommittee on Courts and Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive?" -- A Brief History of Hatch-Waxman -- Authorized Generics -- Patent Settlements -- Testimony of Bret M. Dickey, Senior Vice President, Compass Lexecon, before the Subcommittee on Courts and Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive?" -- Appendix. An Economic Assessment of Patent Settlements in the Pharmaceutical Industry -- Executive Summary -- Introduction -- I. Competition in the Pharmaceutical Industry -- A. Innovation and Patent Protection -- B. Generic Competition -- C. The Hatch-Waxman Amendments -- 1. Introduction -- 2. FDA approval prior to Hatch-Waxman -- 3. Overview of Hatch-Waxman -- 4. Patent litigation under Hatch-Waxman -- D. Patent Litigation and Settlement Agreements -- II. Competitive Effects of Patent Settlements: Short-Run -- A. Overview -- 1. Patent settlements reduce the direct and indirect costs of litigation -- 2. Patent settlements have the potential to be anticompetitive. B. Economic Framework -- 1. Basic Model -- 2. Litigation costs -- 3. Risk aversion -- 4. Information asymmetries -- III. Competitive Effects of Reverse Payment Settlements: Short-Run -- A. Overview -- B. Regulatory and Judicial Enforcement -- 1. History -- 2. Current status -- C. "Reverse Payment" and "Exclusion Payments" Are Misnomers -- D. Basic Economic Model -- E. Introducing Real-World Complexities to the Basic Model60 -- 1. Overview -- 2. Cash payments with litigation costs and/or risk aversion -- 3. Cash payments with a cash-strapped generic -- 4. Cash payments with an optimistic generic -- 5. Cash payments with information asymmetries -- 6. Collateral business agreements -- IV. Long-Run Competitive Effects -- V. Policy Implications and Conclusions -- End Notes -- Statement of Guy Donatiello, Endo Pharmaceuticals Inc., before the Subcommittee on Courts and Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive?" -- Statement of William P. (Bill) Kennedy, Co-Owner, Nephron Pharmaceuticals Corporation, before the U.S. House of Representatives, Hearing on "H.R. 1706, the Protecting Consumer Access to Generic Drugs Act of 2009" -- Company Profile -- Introduction -- The Challenge -- The Position of Nephron Pharmaceuticals Corporation on H.R. 1706 -- Nephron's Recommendation for H.R. 1706 -- End Notes -- Testimony of William Vaughan, Senior Health Analyst, Consumers Union, Non-Profit Publisher of Consumer Reports, before the Subcommittee on Courts and Competition Policy, Hearing on "Pay to Delay: Are Patent Settlements that Delay Generic Drug Market E... -- Rapid Entry of Generic Drugs Can Help Dampen High Health Care Costs Now, Assisting Families and Governments in a Difficult Time -- High Costs Impact Familie -- Costs of Drugs Impact Governments and Taxpayers. Generics Dramatically Lower Costs -- Many Generics about to Enter Market -- The Dynamics of Generic Drug Competition Create Powerful Incentives for Brand-Name and Generic Companies to Settle Patent Litigation in A Way that Thwarts the Objectives of the Hatch-Waxman Act -- Other Legislative Suggestions to Help Speed Generic Entry -- Finding Other Ways to Help Consumers Hold Down Drug Costs While Promoting Drug Innovation -- Appendix #1 -- Best Buy Drug Campaign -- Appendix #2 -- The Hatch-Waxman Act Exacerbates the Incentive to Settle Patent Litigation with Compensation Paid to the Generic Applicant -- These Settlements Are Contrary to the Purpose of the Hatch-Waxman Act -- Experience Shows that Brand-Name Companies and Generic Applicants Do Not Need to Use Payments for Delay to Settle Patent Litigation -- The Courts are Unlikely to Provide Timely Relief to Consumers -- End Notes -- Chapter Sources -- Index -- Blank Page. |
| Record Nr. | UNINA-9910807670403321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor
| Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (238 p.) |
| Disciplina | 616.99/436 |
| Altri autori (Persone) | CheminIsabelle <1965-> |
| Collana | Cancer etiology, diagnosis and treatments |
| Soggetto topico | Liver - Cancer |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61470-776-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Epidemiology of hepatocellular carcinoma -- section 2. Promising new biomarkers for hepatocellular carcinoma. |
| Record Nr. | UNINA-9910452898903321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor
| Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (238 p.) |
| Disciplina | 616.99/436 |
| Altri autori (Persone) | CheminIsabelle <1965-> |
| Collana | Cancer etiology, diagnosis and treatments |
| Soggetto topico | Liver - Cancer |
| ISBN | 1-61470-776-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Epidemiology of hepatocellular carcinoma -- section 2. Promising new biomarkers for hepatocellular carcinoma. |
| Record Nr. | UNINA-9910779621203321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor
| Hepatocellular carcinoma [[electronic resource] ] : a global challenge / / Isabelle Chemin, editor |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (238 p.) |
| Disciplina | 616.99/436 |
| Altri autori (Persone) | CheminIsabelle <1965-> |
| Collana | Cancer etiology, diagnosis and treatments |
| Soggetto topico | Liver - Cancer |
| ISBN | 1-61470-776-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Epidemiology of hepatocellular carcinoma -- section 2. Promising new biomarkers for hepatocellular carcinoma. |
| Record Nr. | UNINA-9910816819103321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors
| Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (155 p.) |
| Disciplina | 616.362 |
| Altri autori (Persone) |
SungJiang Shi
VoungMao Kang |
| Collana | Hepatology research and clinical developments |
| Soggetto topico |
Liver - Diseases
Peritonitis |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61942-084-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""LIVER DISEASE AND PERITONITISCAUSES, TREATMENT AND PREVENTION""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""CHAPTER 1. Systemic Immuno-Inflammatory Response to Severe Peritonitis""; ""Anatomy of the Peritoneal Membrane""; ""Physiology of the Peritoneal Membrane""; ""Response of the PeritonealMembrane to Injury""; ""From Immune Response to SecondaryPeritonitis to Severe Sepsis, Septic Shockand Multiple Organ Dysfunction Syndrome""; ""Sepsis, Severe Sepsis,Septic Shock and Mods""; ""Definitions""
""Contribution of Genes Polymorphism toSusceptibility and Outcome of SepsisAssociated with Peritonitis""""Infection and Inflammation inSecondary Peritonitis""; ""References""; ""CHAPTER 2. Pediatric Non-Alcoholic FattyLiver Disease""; ""Abstract""; ""Introduction""; ""Prevalence of NAFLD""; ""Pathophysiology of NAFLD""; ""Demographics, Genetic Predispositionsand Risk Factors for NAFLD""; ""Natural History and Metabolic andNutritional Profile of NAFLD""; ""Development of NAFLD, NASH and End Stage Liver Disease""; ""Approach to Diagnosis of NAFLD""; ""Clinical Presentation"" ""Diagnosis - Laboratory Evaluations""""Radiological Evaluation""; ""Ultrasound""; ""CT Scan""; ""Magnetic Resonance Imaging""; ""Magnetic Resonance Spectroscopy (MRS)""; ""Fibrosan""; ""Histologic Evaluation""; ""Biomarkers""; ""Management""; ""Diet Lifestyle Modifications""; ""Pharmacologic Interventions""; ""Antiobesity""; ""Attenuation of Insulin Resistance""; ""Metformin""; ""Thiazolidinediones""; ""Antioxidants""; ""Bariatric Surgery""; ""Liver Transplantation for NASH""; ""Conclusion""; ""References""; ""CHAPTER 3. Peritonitis in Cirrhosis:Pathogenesis, Diagnosis andTherapy"" ""Abstract""""Introduction""; ""Pathogenesis""; ""Clinical Manifestations ofSBP and Diagnosis""; ""Ascitic Fluid Cell Analysis""; ""Ascitic Fluid Culture""; ""SBP Variants""; ""Therapy of SpontaneousBacterial Peritonitis""; ""Prophylaxis of SpontaneousBacterial Peritonitis""; ""Cirrhotic Patients with Gastrointestinal Haemorrhage""; ""Patients with Low Ascitic Fluid Protein Concentration and NoPrior History of SBP""; ""Patients with a Previous History of SBP""; ""References""; ""CHAPTER 4. Ethnic Disparities in LiverDiseases""; ""Abstract""; ""Viral Hepatitis: HBV and HCV""; ""Conclusion"" ""References""""CHAPTER 5. Alteration of Adhesion Molecules Expression and Cellular Polarityin Liver Diseases""; ""Abstract""; ""1. Expression of Adhesion Moleculesin the Normal Liver""; ""2. Expression of Adhesion Molecules inCirrhotic Liver and Liver Cell Adenomas""; ""3. Expression of Adhesion Molecules in HCCs""; ""4. Alteration of Cellular Polarity in Hccs""; ""5. Pathophysiological Roles of Alteration of Adhesion Molecules Expression and Cellular Polarity""; ""6. Mechanisms of Alteration of Adhesion Molecules Expression in HCCs"" ""7. Some Adhesion Moleculescould be used for the Diagnostic approach of HCC"" |
| Record Nr. | UNINA-9910452952003321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors
| Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (155 p.) |
| Disciplina | 616.362 |
| Altri autori (Persone) |
SungJiang Shi
VoungMao Kang |
| Collana | Hepatology research and clinical developments |
| Soggetto topico |
Liver - Diseases
Peritonitis |
| ISBN | 1-61942-084-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""LIVER DISEASE AND PERITONITISCAUSES, TREATMENT AND PREVENTION""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""CHAPTER 1. Systemic Immuno-Inflammatory Response to Severe Peritonitis""; ""Anatomy of the Peritoneal Membrane""; ""Physiology of the Peritoneal Membrane""; ""Response of the PeritonealMembrane to Injury""; ""From Immune Response to SecondaryPeritonitis to Severe Sepsis, Septic Shockand Multiple Organ Dysfunction Syndrome""; ""Sepsis, Severe Sepsis,Septic Shock and Mods""; ""Definitions""
""Contribution of Genes Polymorphism toSusceptibility and Outcome of SepsisAssociated with Peritonitis""""Infection and Inflammation inSecondary Peritonitis""; ""References""; ""CHAPTER 2. Pediatric Non-Alcoholic FattyLiver Disease""; ""Abstract""; ""Introduction""; ""Prevalence of NAFLD""; ""Pathophysiology of NAFLD""; ""Demographics, Genetic Predispositionsand Risk Factors for NAFLD""; ""Natural History and Metabolic andNutritional Profile of NAFLD""; ""Development of NAFLD, NASH and End Stage Liver Disease""; ""Approach to Diagnosis of NAFLD""; ""Clinical Presentation"" ""Diagnosis - Laboratory Evaluations""""Radiological Evaluation""; ""Ultrasound""; ""CT Scan""; ""Magnetic Resonance Imaging""; ""Magnetic Resonance Spectroscopy (MRS)""; ""Fibrosan""; ""Histologic Evaluation""; ""Biomarkers""; ""Management""; ""Diet Lifestyle Modifications""; ""Pharmacologic Interventions""; ""Antiobesity""; ""Attenuation of Insulin Resistance""; ""Metformin""; ""Thiazolidinediones""; ""Antioxidants""; ""Bariatric Surgery""; ""Liver Transplantation for NASH""; ""Conclusion""; ""References""; ""CHAPTER 3. Peritonitis in Cirrhosis:Pathogenesis, Diagnosis andTherapy"" ""Abstract""""Introduction""; ""Pathogenesis""; ""Clinical Manifestations ofSBP and Diagnosis""; ""Ascitic Fluid Cell Analysis""; ""Ascitic Fluid Culture""; ""SBP Variants""; ""Therapy of SpontaneousBacterial Peritonitis""; ""Prophylaxis of SpontaneousBacterial Peritonitis""; ""Cirrhotic Patients with Gastrointestinal Haemorrhage""; ""Patients with Low Ascitic Fluid Protein Concentration and NoPrior History of SBP""; ""Patients with a Previous History of SBP""; ""References""; ""CHAPTER 4. Ethnic Disparities in LiverDiseases""; ""Abstract""; ""Viral Hepatitis: HBV and HCV""; ""Conclusion"" ""References""""CHAPTER 5. Alteration of Adhesion Molecules Expression and Cellular Polarityin Liver Diseases""; ""Abstract""; ""1. Expression of Adhesion Moleculesin the Normal Liver""; ""2. Expression of Adhesion Molecules inCirrhotic Liver and Liver Cell Adenomas""; ""3. Expression of Adhesion Molecules in HCCs""; ""4. Alteration of Cellular Polarity in Hccs""; ""5. Pathophysiological Roles of Alteration of Adhesion Molecules Expression and Cellular Polarity""; ""6. Mechanisms of Alteration of Adhesion Molecules Expression in HCCs"" ""7. Some Adhesion Moleculescould be used for the Diagnostic approach of HCC"" |
| Record Nr. | UNINA-9910779531303321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors
| Liver disease and peritonitis [[electronic resource] ] : causes, treatment and prevention / / Mao Kang Voung and Jiang Shi Sung, editors |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2012 |
| Descrizione fisica | 1 online resource (155 p.) |
| Disciplina | 616.362 |
| Altri autori (Persone) |
SungJiang Shi
VoungMao Kang |
| Collana | Hepatology research and clinical developments |
| Soggetto topico |
Liver - Diseases
Peritonitis |
| ISBN | 1-61942-084-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""LIVER DISEASE AND PERITONITISCAUSES, TREATMENT AND PREVENTION""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""CHAPTER 1. Systemic Immuno-Inflammatory Response to Severe Peritonitis""; ""Anatomy of the Peritoneal Membrane""; ""Physiology of the Peritoneal Membrane""; ""Response of the PeritonealMembrane to Injury""; ""From Immune Response to SecondaryPeritonitis to Severe Sepsis, Septic Shockand Multiple Organ Dysfunction Syndrome""; ""Sepsis, Severe Sepsis,Septic Shock and Mods""; ""Definitions""
""Contribution of Genes Polymorphism toSusceptibility and Outcome of SepsisAssociated with Peritonitis""""Infection and Inflammation inSecondary Peritonitis""; ""References""; ""CHAPTER 2. Pediatric Non-Alcoholic FattyLiver Disease""; ""Abstract""; ""Introduction""; ""Prevalence of NAFLD""; ""Pathophysiology of NAFLD""; ""Demographics, Genetic Predispositionsand Risk Factors for NAFLD""; ""Natural History and Metabolic andNutritional Profile of NAFLD""; ""Development of NAFLD, NASH and End Stage Liver Disease""; ""Approach to Diagnosis of NAFLD""; ""Clinical Presentation"" ""Diagnosis - Laboratory Evaluations""""Radiological Evaluation""; ""Ultrasound""; ""CT Scan""; ""Magnetic Resonance Imaging""; ""Magnetic Resonance Spectroscopy (MRS)""; ""Fibrosan""; ""Histologic Evaluation""; ""Biomarkers""; ""Management""; ""Diet Lifestyle Modifications""; ""Pharmacologic Interventions""; ""Antiobesity""; ""Attenuation of Insulin Resistance""; ""Metformin""; ""Thiazolidinediones""; ""Antioxidants""; ""Bariatric Surgery""; ""Liver Transplantation for NASH""; ""Conclusion""; ""References""; ""CHAPTER 3. Peritonitis in Cirrhosis:Pathogenesis, Diagnosis andTherapy"" ""Abstract""""Introduction""; ""Pathogenesis""; ""Clinical Manifestations ofSBP and Diagnosis""; ""Ascitic Fluid Cell Analysis""; ""Ascitic Fluid Culture""; ""SBP Variants""; ""Therapy of SpontaneousBacterial Peritonitis""; ""Prophylaxis of SpontaneousBacterial Peritonitis""; ""Cirrhotic Patients with Gastrointestinal Haemorrhage""; ""Patients with Low Ascitic Fluid Protein Concentration and NoPrior History of SBP""; ""Patients with a Previous History of SBP""; ""References""; ""CHAPTER 4. Ethnic Disparities in LiverDiseases""; ""Abstract""; ""Viral Hepatitis: HBV and HCV""; ""Conclusion"" ""References""""CHAPTER 5. Alteration of Adhesion Molecules Expression and Cellular Polarityin Liver Diseases""; ""Abstract""; ""1. Expression of Adhesion Moleculesin the Normal Liver""; ""2. Expression of Adhesion Molecules inCirrhotic Liver and Liver Cell Adenomas""; ""3. Expression of Adhesion Molecules in HCCs""; ""4. Alteration of Cellular Polarity in Hccs""; ""5. Pathophysiological Roles of Alteration of Adhesion Molecules Expression and Cellular Polarity""; ""6. Mechanisms of Alteration of Adhesion Molecules Expression in HCCs"" ""7. Some Adhesion Moleculescould be used for the Diagnostic approach of HCC"" |
| Record Nr. | UNINA-9910820928903321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Starch science progress [[electronic resource] /] / Luybov A. Wasserman ... [et al.]
| Starch science progress [[electronic resource] /] / Luybov A. Wasserman ... [et al.] |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2011 |
| Descrizione fisica | 1 online resource (199 p.) |
| Disciplina | 660.6/3 |
| Altri autori (Persone) | WassermanLuybov A |
| Collana | Biotechnology in agriculture, industry and medicine |
| Soggetto topico |
Starch
Chemical technology |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61122-156-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910461460203321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Starch science progress [[electronic resource] /] / Luybov A. Wasserman ... [et al.]
| Starch science progress [[electronic resource] /] / Luybov A. Wasserman ... [et al.] |
| Pubbl/distr/stampa | New York, : Nova Biomedical/Nova Science Publishers, c2011 |
| Descrizione fisica | 1 online resource (199 p.) |
| Disciplina | 660.6/3 |
| Altri autori (Persone) | WassermanLuybov A |
| Collana | Biotechnology in agriculture, industry and medicine |
| Soggetto topico |
Starch
Chemical technology |
| ISBN | 1-61122-156-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910790033703321 |
| New York, : Nova Biomedical/Nova Science Publishers, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
